U.S. tariffs on Canada have put experts at odds over how appropriate the action was, particularly given the unaddressed ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

In many cases big pharma companies like to hedge their bets ... are strong – but it still meant sharing profits with an arch-rival. We’ll never know for sure but from the outside it looks ...

S&P 500 E-Mini futures (ESH25) are down -0.90%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -1.04% this morning, ...

S&P 500 E-Mini futures (ESH25) are trending up +0.56% this morning as investors gear up for the release of crucial U.S.

COUR Pharmaceuticals attracted no fewer than three big pharma backers for its $107 million ... to switch off its effects if needed. New investor ARCH Venture Partners led the round, with ...

Arch Capital's stock has been volatile, impacted by California wildfire losses, but core business performance remains strong.

Prior to 60 Minutes' March 9, 2025 broadcast, which featured correspondent Cecilia Vega's report on the Purdue Pharma bankruptcy case, we reached out to Purdue Pharma for comment on our story ...

Streamlining firmwide workflows and automating processes to enhance RSM’s efficiency in managing alternative investments Arch, a digital Alternatives Management Platform modernizing workflows ...

The new arch that signifies the end of the Iditarod Trail Sled Dog Race arrived in Nome last week. The 27-feet-wide log, tightly wrapped in mover’s blankets and shrink-wrap, was carefully ...

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares opened today at $1.14. Effectively assess a stock ...